Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
The APDN news archive on Stock Titan covers the historical disclosures and announcements of Applied DNA Sciences, Inc., a biotechnology company that developed and commercialized polymerase chain reaction (PCR)-based technologies for DNA production and detection and later adopted a BNB-focused digital asset treasury strategy. During the period when it traded under the Nasdaq symbol APDN, the company issued news on operational restructuring, platform development, customer activity, and capital markets transactions.
Readers can review company updates describing the transition to a pure play provider of synthetic DNA and mRNA manufacturing solutions through its majority-owned subsidiary LineaRx, Inc., including the focus on its LineaDNA, LineaRNAP, and LineaIVT platforms. News items detail workforce reductions, the exit from DNA tagging and security products and services, the closure of Applied DNA Clinical Labs, and the consolidation of operations behind LineaRx to support advanced biotherapeutics and diagnostic applications.
The archive also includes announcements related to conference participation and scientific posters showcasing the LineaDNA and LineaIVT platforms, follow-on orders for LineaDNA from a global in vitro diagnostics manufacturer for use in a cancer diagnostic application, and engagements with mRNA-focused contract development and manufacturing organizations. Financial news covers quarterly results, non-GAAP metrics such as Adjusted EBITDA and monthly net cash burn, and commentary on cost optimization and capital allocation.
Later APDN news releases document the company’s initiation of a BNB-focused digital asset treasury strategy, private placement commitments to fund BNB acquisitions, and the planned change of its Nasdaq ticker from APDN to BNBX to reflect this strategic focus. These items describe agreements with Cypress LLC and Cypress Management LLC for digital asset management and advisory services, as well as the involvement of institutional and crypto-native investors. By following this archive, investors can trace how APDN evolved from a biotechnology-focused issuer into BNB Plus Corp. (BNBX) with a combined profile in nucleic acid production and digital asset treasury management.
Applied DNA Sciences (NASDAQ: APDN) has launched business development initiatives to promote its LinearDNA™ platform, a cell-free enzymatic DNA production method aimed at enhancing the biotherapeutics sector's efficiency. The company, through its subsidiary LineaRx, is advocating LinearDNA as a viable alternative to traditional plasmid-based DNA production, claiming advantages in speed, purity, flexibility, and scalability. Key applications include DNA vaccines, mRNA production, and gene therapy manufacturing, with preclinical studies showing linDNA's effectiveness.
Applied DNA Sciences (NASDAQ: APDN) is advancing its CertainT® platform as a U.S.-made solution to demonstrate goods’ origins, adhering to the Uyghur Forced Labor Prevention Act (UFLPA) effective from June 21, 2022. The UFLPA bans imports from China's Xinjiang region due to forced labor concerns. The Department of Homeland Security recognizes DNA traceability and isotopic testing as methods to prove compliance. With a focus on securing global supply chains, Applied DNA aims for industry adoption of its technology, which has significant implications for cotton sourcing and overall supply chain security.
Applied DNA Sciences (NASDAQ: APDN) has announced the initiation of its first canine clinical trial for a lymphoma cancer vaccine, based on a peer-reviewed study published in The Journal of Experimental & Clinical Cancer Research. This study supports the use of the company’s LinearDNA™ platform, demonstrating promising preclinical data indicating a strong immune response in canine models. The vaccine targets B-cell lymphoma, the most common cancer in dogs, with plans for a trial to begin this year. This innovation could lead to a conditional license application with the USDA.
Applied DNA Sciences (NASDAQ: APDN) reported a record revenue of $6.1 million for Q2 FY2022, marking a 130% year-over-year increase and 48% sequential growth. The company has cash reserves of $6.5 million post a registered direct offering. Demand for COVID-19 testing remains strong, driven by academic and corporate clients. The company is advancing its LinearDNA platform and expects to commercialize RNA-based therapeutics. Despite a net loss of $1.8 million, the outlook for continued revenue growth remains positive.
Applied DNA Sciences (NASDAQ: APDN) will report its fiscal 2022 second quarter financial results on May 12, 2022, after market close. The management team will host a conference call at 4:30 p.m. ET to discuss the results, which will also be available via webcast. Applied DNA specializes in enzymatic DNA production, particularly through its LinearDNA platform, which supports various applications including in vitro diagnostics and therapeutic developments. More information can be found on their website.
Applied DNA Sciences (NASDAQ: APDN) has secured a safeCircle™ health services contract with a New York City investment firm for PCR-based COVID-19 testing. Starting in April 2022, the contract includes testing services for employees returning to in-person work. The safeCircle platform offers a comprehensive health testing solution, managing sample distribution, results reporting, and variant tracking. Mike Munzer from Applied DNA emphasized the importance of managing COVID-19 exposure as companies transition back to the office environment.
Applied DNA Sciences (NASDAQ: APDN) announced that CEO Dr. James A. Hayward will present at the 2022 Virtual Growth Conference hosted by Maxim Group LLC from March 28-30, 2022. The presentation will be available on-demand during the event. The conference will cover various sectors, including biotech and healthcare, and feature multiple presentations, discussions, and Q&A sessions. Applied DNA is known for its LinearDNA platform utilized in diagnostics and drug development. For more details, visit adnas.com.
Applied DNA Sciences (NASDAQ: APDN) and Spindle Biotech have signed a non-binding letter of intent to explore a collaboration on mRNA production. The partnership aims to utilize Applied DNA's LinearDNA™ platform to create chemically modified DNA templates for Spindle's advanced RNA polymerase. This integration is expected to enhance yield and simplify the production process, offering up to a ten-fold improvement in yield compared to traditional methods. The final agreement's execution depends on successful negotiations between the two parties.
Applied DNA Sciences (NASDAQ: APDN) announced a virtual fireside chat hosted by CEO Dr. James A. Hayward on March 14, 2022, during the 34th Annual Roth Investor Conference. The session will cover the company’s advancements in Polymerase Chain Reaction (PCR)-based DNA technologies. Key executives, including CFO Beth Jantzen and Clay Shorrock, will also conduct one-on-one investor meetings. Interested investors can request a meeting via email at oneononerequests@roth.com. Full details will be available on their website.
Applied DNA Sciences (NASDAQ: APDN) has successfully closed a registered direct offering of 1,496,400 shares of common stock at a price of $2.80 per share, yielding gross proceeds of approximately $4.2 million. Concurrently, the company issued unregistered warrants to purchase an equal number of shares. Following the offering, total outstanding shares will amount to 8,234,320. The net proceeds are intended for general corporate purposes, including advancing its LinearDNA manufacturing platform.
FAQ
What is the current stock price of Applied Dna Scie (APDN)?
What is the market cap of Applied Dna Scie (APDN)?
